WOONSOCKET, R.I., Dec. 9, 2024
/PRNewswire/ -- CVS Health Corporation ("CVS Health", NYSE: CVS)
announced today the results of the previously announced cash tender
offer (the "Any and All Tender Offer") for any and all of its
4.100% Senior Notes due 2025 (the "Any and All Notes").
As of 5:00 p.m., New York City time, on December 6, 2024 (the "Any and All Expiration
Date") as reported by D.F. King & Co., Inc., the Tender and
Information Agent for the Any and All Tender Offer, the principal
amount of the Any and All Notes listed in the table below has been
validly tendered and not validly withdrawn, or tendered pursuant to
the guaranteed delivery procedures (the "Guaranteed Delivery
Procedures") described in the Offer to Purchase dated December 2, 2024 (as amended or supplemented from
time to time, the "Offer to Purchase"). In order to be eligible to
participate in the Any and All Tender Offer, holders (individually,
a "Holder" and collectively, the "Holders") of Any and All Notes
tendered pursuant to the Guaranteed Delivery Procedures at or prior
to the Any and All Expiration Date must deliver such Any and All
Notes to CVS Health at or prior to 5:00
p.m., New York City time,
on December 10, 2024 (the "Any and
All Guaranteed Delivery Expiration Date") (unless extended by CVS
Health as described in the Offer to Purchase).
In addition to the Any and All Tender Offer, CVS Health
previously announced its Maximum Tender Offer (as defined in the
Offer to Purchase) for the Maximum Tender Offer Notes (as defined
in the Offer to Purchase, and collectively with the Any and All
Notes, the "Notes") concurrently with the Any and All Tender Offer.
The maximum purchase price in the Maximum Tender Offer, not
including Accrued Interest (as defined below) (such maximum
purchase price, the "Maximum Tender Offer Amount"), is equal to
$2,000,000,000 less the
aggregate purchase price, not including Accrued Interest, paid or
payable in respect of the Any and All Notes validly tendered and
accepted for purchase. Because $5,000
aggregate principal amount of the Any and All Notes remain subject
to the Guaranteed Delivery Procedures, the Maximum Tender Offer
Amount is subject to change. Holders are urged to read the Offer to
Purchase carefully before making any decision with respect to the
Maximum Tender Offer.
Holders of all Any and All Notes validly tendered and not
validly withdrawn at or prior to the Any and All Expiration Date
and accepted for purchase were eligible to receive the applicable
Total Consideration set forth in the table below, plus accrued and
unpaid interest ("Accrued Interest") up to, but not including, the
settlement date of the Any and All Tender Offer. For the avoidance
of doubt, Accrued Interest payable with respect to Any and All
Notes validly tendered pursuant to the Guaranteed Delivery
Procedures and accepted for purchase shall cease to accrue on the
Any and All Settlement Date (as defined below).
Any and All Notes:
Title of
Notes
|
CUSIP
Number
|
Original
Issuer
|
Principal Amount
Outstanding
|
Maturity
Date
|
Principal Amount
Tendered
|
Principal Amount
Tendered Pursuant
to Guaranteed
Delivery
Procedures
|
4.100% Senior Notes due
2025
|
126650CW8
|
CVS Health
Corporation
|
$950,087,000
|
3/25/2025
|
$225,979,000
|
$5,000
|
The settlement date for the Any and All Notes validly tendered
at or prior to the Any and All Expiration Date, or validly tendered
pursuant to the Guaranteed Delivery Procedures, and accepted for
purchase is expected to be December 11,
2024, the third business day following the Any and All
Expiration Date (the "Any and All Settlement Date").
CVS Health expects that it will accept for purchase all of the
Any and All Notes validly tendered at or prior to the Any and All
Expiration Date, and all Any and All Notes delivered at or prior to
the Any and All Guaranteed Delivery Expiration Date. CVS
Health will fund the purchase of the Any and All Notes with part of
the proceeds from the issuance of CVS Health's 7.000% Series A
Junior Subordinated Notes due 2055 and 6.750% Series B Junior
Subordinated Notes due 2054 (the "New Notes").
CVS Health has retained Barclays Capital Inc. and Mizuho
Securities USA LLC to act as
Dealer Managers for the Tender Offers (as defined in the Offer to
Purchase). D.F. King & Co., Inc. has been retained to act as
the Tender and Information Agent for the Tender Offers. The Offer
to Purchase may be accessed at the following link:
http://www.dfking.com/cvs. Requests for assistance relating to the
procedures for tendering Notes (as defined in the Offer to
Purchase) may be directed to the Tender and Information Agent
either by email at cvs@dfking.com, or by phone (212) 269-5550 (for
banks and brokers only) or (800) 487-4870 (for all others toll
free). Requests for assistance relating to the terms and conditions
of the Tender Offers may be directed to Barclays Capital Inc. at
(800) 438-3242 (toll free) or (212) 528-7581 (collect) or Mizuho
Securities USA LLC at (866)
271-7403 (toll-free) or (212) 205-7741. Beneficial owners may also
contact their broker, dealer, commercial bank, trust company or
other nominee for assistance.
This press release does not constitute an offer to sell or
purchase, or a solicitation of an offer to sell or purchase, or the
solicitation of tenders with respect to, any securities, including
the Notes or the New Notes. No offer, solicitation, purchase or
sale will be made in any jurisdiction in which such an offer,
solicitation, or sale would be unlawful. The Tender Offers are
being made solely pursuant to the Offer to Purchase made available
to Holders of the Notes. None of CVS Health, the Board of Directors
of CVS Health, the Dealer Managers, Tender and Information Agent or
the trustees with respect to the Notes, or any of their respective
affiliates, is making any recommendation as to whether or not
Holders should tender or refrain from tendering all or any portion
of their Notes in response to the Tender Offers. Holders are urged
to evaluate carefully all information in the Offer to Purchase,
consult their own investment and tax advisers and make their own
decisions whether to tender Notes in the Tender Offers, and, if so,
the principal amount of Notes to tender.
About CVS Health
CVS Health is a leading health solutions company building a
world of health around every consumer it serves and connecting care
so that it works for people wherever they are. As of September 30, 2024, the Company had more than
9,000 retail locations, more than 900 walk-in medical clinics, more
than 225 primary care medical clinics, a leading pharmacy benefits
manager with approximately 90 million plan members and expanding
specialty pharmacy solutions, and a dedicated senior pharmacy care
business serving more than 800,000 patients per year. The Company
also serves an estimated more than 36 million people through
traditional, voluntary and consumer-directed health insurance
products and related services, including expanding Medicare
Advantage offerings and a leading standalone Medicare Part D
prescription drug plan. The Company is creating new sources of
value through its integrated model allowing it to expand into
personalized, technology driven care delivery and health services,
increasing access to quality care, delivering better health
outcomes and lowering overall health care costs.
Forward-Looking Statements
This press release contains forward-looking statements. The
Private Securities Litigation Reform Act of 1995 provides a safe
harbor for forward-looking statements made by or on behalf of CVS
Health. By their nature, all forward-looking statements are not
guarantees of future performance or results and are subject to
risks and uncertainties that are difficult to predict and/or
quantify. Actual results may differ materially from those
contemplated by the forward-looking statements due to the risks and
uncertainties described in our Securities and Exchange Commission
filings, including those set forth in the Risk Factors section and
under the heading "Cautionary Statement Concerning Forward-Looking
Statements" in our most recently filed Annual Report on Form 10-K,
our Quarterly Reports on Form 10-Q for the quarterly periods ended
March 31, 2024, June 30, 2024 and September 30, 2024 and our Current Reports on
Form 8-K.
You are cautioned not to place undue reliance on CVS Health's
forward-looking statements. CVS Health's forward-looking statements
are and will be based upon management's then-current views and
assumptions regarding future events and operating performance, and
are applicable only as of the dates of such statements. CVS Health
does not assume any duty to update or revise forward-looking
statements, whether as a result of new information, future events,
uncertainties or otherwise.
Investor
Contact:
|
|
Larry McGrath
Executive Vice President
Chief Strategy Officer &
Chief Strategic Advisor to the CEO
investorinfo@cvshealth.com
|
|
Media
Contact:
|
|
Ethan
Slavin
860-273-6095
Ethan.Slavin@CVSHealth.com
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cvs-health-corporation-announces-expiration-and-results-of-any-and-all-tender-offer-302325595.html
SOURCE CVS Health